University of Chicago Medical Center

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

• University of Chicago Medical Center

  Chicago, Illinois 60637

  171 vizsgálat

• The University of Chicago Medical Center

  Chicago, Illinois 60637

  38 vizsgálat

• The University of Chicago Medical Center (UCMC)

  Chicago, Illinois 60637

  11 vizsgálat

• UChicago Medicine - River East

  Chicago, Illinois 60611

  6 vizsgálat

• The University of Chicago Medical Center - Duchossois Center for Advanced Medicine

  Chicago, Illinois 60637

  3 vizsgálat

  • NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

    Contact: Qinhan Chen

  • NCT06290934Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  • NCT05169684A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

• The University of Chicago Medical Center - Hyde Park - Hematology & Oncology

  Chicago, Illinois 60637

  3 vizsgálat

  • NCT06452277A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • NCT05537740A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

  • NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

• UChicago Medicine

  Chicago, Illinois 60637

  3 vizsgálat

  • NCT07053436Horizon Two: HR NDMM (MMRC-100)

    Contact: Joanna Pagacz

  • NCT04294927TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

    Contact: Kathryn Mills

  • NCT03944798Surveillance AFter Extremity Tumor surgerY

• The University of Chicago Medical Center - Oncology

  Chicago, Illinois 60637

  2 vizsgálat

  • NCT07169734A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

    Contact: Principal Investigator

  • NCT06747585A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

• The University of Chicago Medical Center (UCMC) Duchossois Center for Advanced Medicine (DCAM)

  Chicago, Illinois 60637

  2 vizsgálat

  • NCT05427812Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

  • NCT04959448Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

• UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology

  Chicago, Illinois 60637

  2 vizsgálat

  • NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  • NCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

• The University of Chicago Medical Center - Accepting Adult and Adolescent Patients

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06121297RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

    Contact: Dr. Cuoghi Edens, MD, FAAP

• The University of Chicago Medical Center - Accepting Adult and Juvenile Patients

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

    Contact: Dr. Iazsmin Ventura, MD (principal investigator)

• The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT03269136PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

• The University of Chicago Medical Center /ID# 114115

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

• The University of Chicago Medical Center /ID# 151395

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT02899052Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

• The University of Chicago Medical Center /ID# 153673

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT02942290A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

• The University of Chicago Medical Center /ID# 155264

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT02988960A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

• The University of Chicago Medical Center /ID# 157124

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• The University of Chicago Medical Center /ID# 160511

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• The University of Chicago Medical Center /ID# 165429

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT03314181A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

• The University of Chicago Medical Center /ID# 203216

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• The University of Chicago Medical Center /ID# 252870

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

• The University of Chicago Medical Center /ID# 255674

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT06109272A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

• The University of Chicago Medical Center /ID# 262259

  Chicago, Illinois 60637-1443

  1 vizsgálat

  • NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• The University of Chicago Medical Center, Investigational Drug Service Department of Pharmacy

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT01889238Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

• The University of Chicago Medical Center - Neurology

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

• The University of Chicago Medical Center (Site 0004)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

• The University of Chicago Medical Center (Site 0007)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

• The University of Chicago Medical Center (Site 0047)

  Chicago, Illinois 60637-1447

  1 vizsgálat

  • NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

• The University of Chicago Medical Center (Site 0118)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

• The University of Chicago Medical Center (Site 1539)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

• The University of Chicago Medical Centre

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT04778397Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

• Univ Chicago Medical Center

  Chicago, Illinois

  1 vizsgálat

  • NCT01844986Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

• University of Chicago Medical Center, Biological Science Division

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07713849Transition Care for FEP

    Contact: Madeline Perez Lab Manager, B.S

• University of Chicago Medical Center, CCD

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06760637Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

• University of Chicago Medical Center - Duchossis Center for Advanced Medicine

  Chicago, Illinois 60637-1426

  1 vizsgálat

  • NCT04919642Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

• University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT03394365A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    Contact: Data Protection Officer

• University of Chicago Medical Center /ID# 218611

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT04750226Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

• University of Chicago Medical Center /ID# 256334

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

• University of Chicago Medical Center /ID# 258197

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

• University of Chicago Medical Center /ID# 258491

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

• University of Chicago Medical Center /ID# 261605

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06318273A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

• University of Chicago Medical Center /ID# 263162

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05843643Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

• University of Chicago Medical Center /ID# 267400

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

• University of Chicago Medical Center /ID# 269028

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

• University of Chicago Medical Center /ID# 269546

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

• University of Chicago Medical Center /ID# 270517

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06858813A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

• University of Chicago Medical Center /ID# 271373

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

• University of Chicago Medical Center /ID# 271588

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07071519A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

• University of Chicago Medical Center /ID# 271688

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

• University of Chicago Medical Center /ID# 274742

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

• University of Chicago Medical Center /ID# 274796

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06890338A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

• University of Chicago Medical Center /ID# 275131

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06846320Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

• University of Chicago Medical Center /ID# 275342

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07196644A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

• University of Chicago Medical Center /ID# 276271

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

• University of Chicago Medical Center /ID# 276638

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07241039A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

• University of Chicago Medical Center /ID# 278295

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07278336A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

• University of Chicago Medical Center /ID# 278863

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07409246A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

• University of Chicago Medical Center /ID# 279365

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07525206A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

• University of Chicago Medical Center /ID# 280149

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07365241A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

• University of Chicago Medical Center (Site 0045)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    Contact: Study Coordinator

• University of Chicago Medical Center (Site 0067)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    Contact: Toll Free Number

• University of Chicago Medical Center (Site 0109)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06305767A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

• University of Chicago Medical Center (Site 0120)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

• University of Chicago Medical Center (Site 0126)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06890884A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    Contact: Study Coordinator

• University of Chicago Medical Center (Site 0134)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• University of Chicago Medical Center (Site 0136)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

• University of Chicago Medical Center (Site 0145)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    Contact: Study Coordinator

• University of Chicago Medical Center (Site 0207)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05144841A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

• University of Chicago Medical Center (Site 1007)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

• University of Chicago Medical Center (Site 1037)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

• University of Chicago Medical Center (Site 2828)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT05298423Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

• University of Chicago Medical Center (Site 4037)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

• University of Chicago Medical Center (Site 5002)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Study Coordinator

• University of Chicago Medical Center (Site 5037)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

    Contact: Study Coordinator

• University of Chicago Medical Center (Site 5066)

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• University of Chicago Medical Center- Site Number : 8400017

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06481904Registry for Stage 2 Type 1 Diabetes

• University of Chicago Medical Center- Site Number : 8400018

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06834347A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

• University of Chicago Medical Center- Site Number : 8400055

  Chicago, Illinois 60637

  1 vizsgálat

  • NCT06141486Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis